• Cancel
    Date:2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=560

    PALO ALTO, CA, March 30, 2021 -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1/2 financing. The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Funds Management, and existing investors, including Northern Light Venture Capital and Vivo Capital. In addition, the company received a strategic capital investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP), directed toward advancing the company’s work to treat blood cancers. CEC Capital Group was the exclusive financial advisor on this transaction.

  • Cancel
    Date:2021-03

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2021-03

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2021-03

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2021-03

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2021-03

    CEC Capital Served as Financial Advisor

  • Cancel
    Date:2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=546

    In Shanghai, on February 24, 2021 – WuXi Diagnostic Investment (Cayman) Limited ("WuXi Diagnostics") announced that it has completed US$150 million in series B funding, joined by new investors including Thermo Fisher Scientific Inc. ("Thermo Fisher"), Shiyu Capital ("SHIYU"), ABC International Holdings Limited ("ABC International"), Sunland Capital and CCBI Tech Venture, alongside existing shareholder YF Capital, with CEC Capital Group serving as the exclusive financial adviser. WuXi Diagnostics will deploy funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline, and accelerate market penetration in the global diagnostics sector.

  • Cancel
    Date:2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=546

    In Shanghai, on February 24, 2021 – WuXi Diagnostic Investment (Cayman) Limited ("WuXi Diagnostics") announced that it has completed US$150 million in series B funding, joined by new investors including Thermo Fisher Scientific Inc. ("Thermo Fisher"), Shiyu Capital ("SHIYU"), ABC International Holdings Limited ("ABC International"), Sunland Capital and CCBI Tech Venture, alongside existing shareholder YF Capital, with CEC Capital Group serving as the exclusive financial adviser. WuXi Diagnostics will deploy funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline, and accelerate market penetration in the global diagnostics sector.

  • Cancel
    Date:2021-02

    CEC Capital Served as Financial Advisor